	US 12,282,021 B2
	Stratification of acute myeloid leukaemia patients for sensitivity to kinase pathway inhibitor therapy
Pedro Maria Casado Izquierdo, London (GB); and Pedro Rodriquez Cutillas, London (GB)
Assigned to KINOMICA LIMITED, Macclesfield (GB)
Appl. No. 16/624,549
Filed by KINOMICA LIMITED, Macclesfield (GB)
PCT Filed Jun. 20, 2018, PCT No. PCT/EP2018/066472 § 371(c)(1), (2) Date Dec. 19, 2019, PCT Pub. No. WO2018/234404, PCT Pub. Date Dec. 27, 2018.
Claims priority of application No. 1709917 (GB), filed on Jun. 21, 2017.
Prior Publication US 2020/0393466 A1, Dec. 17, 2020
Int. Cl. G01N 33/574 (2006.01); A61K 31/519 (2006.01); A61K 31/553 (2006.01)

CPC G01N 33/57426 (2013.01) [A61K 31/519 (2013.01); A61K 31/553 (2013.01); G01N 2440/14 (2013.01)]

1 Claim

1. A method of treating an acute myeloid leukemia (AML) patient whose leukemia cells have advanced differentiation status, comprising the steps of:

administering midostaurin to an AML patient whose leukemia cells have advanced differentiation status,

wherein the AML patient whose leukemia cells have advanced differentiation status is identified by having in the leukemia cells of the patient:

(i) a higher than normal expression level of a CD marker selected from the group selected of: CD11b, CD14, CD15, CD16, CD33, CD38, CD44, CD45, CD64, CD123, and HLA-DR, and

(ii) the phosphorylation of one or more phosphorylation sites selected from the group consisting of: GSK3A at pS21; PRKCD at Y313; pT507, pT295, pT218, and/or pS664 of PRKCD; STK10 at pS20 and/or pS13 of STK10; PAK1 at pS144 of PAK1; PAK2 at pS141 of PAK2; MAPK1 at Y187 and/or T185; and MAPK3 at T202 and/or Y204.